Atai Life Sciences N.V. (ATAI) |
|
1.81 0.21 (13.13%)
|
03-31 16:00 |
|
Open: |
1.73 |
Pre. Close: |
1.6 |
|
High:
|
1.88 |
Low:
|
1.7 |
|
Volume:
|
4,327,699 |
Market Cap:
|
359(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:16:51 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 2.19  One year: 2.56 |
| Support: |
Support1: 1.42 Support2: 1.13 |
| Resistance: |
Resistance1: 1.87 Resistance2: 2.19 |
| Pivot: |
1.32 |
| Moving Average: |
MA(5): 1.53 MA(20): 1.35
MA(100): 2.18  MA(250): 3.21 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 88.8 %D(3): 76.6 |
| RSI: |
RSI(14): 67.3 |
| 52-week: |
High: 5.44 Low: 1.13 |
| Average Vol(K): |
3-Month: 1,500 (K) 10-Days: 1,707 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ATAI ] has closed Bollinger Bands are 4.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.7 - 1.71 |
1.71 - 1.71 |
|
Low:
|
1.54 - 1.54 |
1.54 - 1.55 |
|
Close:
|
1.59 - 1.6 |
1.6 - 1.61 |
|
Company Description |
|
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany. |
Headline News |
Sat, 01 Apr 2023
TDR's Top 5 Psychedelic Developments For The Week Of March 27 - The Dales Report
Fri, 31 Mar 2023
Should Biotechnology Stock ATAI Life Sciences NV (ATAI) Be in Your Portfolio Friday? - InvestorsObserver
Thu, 30 Mar 2023
Apeiron Founder Christian Angermayer Makes Follow-On Purchase ... - The Dales Report
Thu, 30 Mar 2023
$1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks ... - Benzinga
Wed, 29 Mar 2023
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are ... - Benzinga
Thu, 23 Mar 2023
Is ATAI Life Sciences NV (ATAI) Stock a Good Value Thursday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
166 (M) |
|
% Held by Insiders
|
1.3676e+008 (%) |
|
% Held by Institutions
|
9.2 (%) |
|
Shares Short
|
4,500 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.4535e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-34 |
|
Return on Assets (ttm)
|
233.8 |
|
Return on Equity (ttm)
|
-22 |
|
Qtrly Rev. Growth
|
425000 |
|
Gross Profit (p.s.)
|
0.12 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-1.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-94 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
4.07e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
